Sotatercept in the Treatment of Pulmonary Arterial Hypertension: A Comprehensive Narrative Review of Mechanism, Efficacy and Future Directions
Article Sidebar
Main Article Content
Abstract
Rationale: Pulmonary Arterial Hypertension (PAH) is a progressive vascular remodeling disease with elevated pulmonary vascular resistance that is lethal. While therapeutic progress was recently made with endothelin, nitric oxide, and prostacyclin pathway-based therapy for the treatment of PAH, the disease is currently incurable with a high cost of morbidity and mortality. Sotatercept, a new activin receptor IIA-Fc fusion protein, may prove to be a game-changer as a therapeutic agent for the treatment of PAH by regulating the growth factor signaling aberration of PAH.
Methods: It is a narrative review of evidence for the drug Sotatercept for Group 1 PAH from a systematic literature search for clinical trials, mechanism studies, and regulatory data up to 2024. Pivotal clinical trials such as PULSAR, SPECTRA, STELLAR, and ZENITH were evaluated for efficacy, safety, and comparative results.
Results: Sotatercept is a TGF-β family member ligand trap that rebalances activin/BMP signaling to target vascular remodeling. Clinically, striking effects were shown with exercise (40.8 m improvement in STELLAR 6MWD), pulmonary hemodynamics (PVR reduction of 146-240 dyn·s·cm-5 in PULSAR), as well as clinical measures (76% reduction of composite morbidity/mortality through ZENITH). On the background with an acceptable drug safety profile of predominantly hematologic effects, as well as injection site reaction, benefits were achieved. Comparison with analyses implies at least similar, if superior in some dimensions, efficacy of current PAH therapies.
Conclusion: Sotatercept is a new therapeutic option for PAH as the first drug to act on the activin/BMP pathway. With its strong effect on several clinically relevant end points, it is a “fourth pillar” of PAH therapy. Clinical trials will determine its place in the algorithm, ascertain other combinations, and potentially identify its utility for other types of pulmonary hypertension.
Article Details
Copyright (c) 2025 Ranjan N, et al.
This work is licensed under a Creative Commons Attribution 4.0 International License.
Galiè N, Humbert M, Vachiery JL, Gibbs S, Lang I, Torbicki A, et al. 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Heart J. 2016 Jan 1;37(1):67-119. Available from: https://doi.org/10.1093/eurheartj/ehv317
Simonneau G, Montani D, Celermajer DS, Denton CP, Gatzoulis MA, Krowka M, et al. Haemodynamic definitions and updated clinical classification of pulmonary hypertension. Eur Respir J. 2019 Jan;53(1):1801913. Available from: https://doi.org/10.1183/13993003.01913-2018
Humbert M, Guignabert C, Bonnet S, Dorfmüller P, Klinger JR, Nicolls MR, et al. Pathology and pathobiology of pulmonary hypertension: state of the art and research perspectives. Eur Respir J. 2019 Jan;53(1):1801887. Available from: https://doi.org/10.1183/13993003.01887-2018
Humbert M, Kovacs G, Hoeper MM, Badagliacca R, Berger RMF, Brida M, et al. 2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Heart J. 2022 Oct 7;43(38):3618-3731. Available from: https://doi.org/10.1093/eurheartj/ehac237
Benza RL, Miller DP, Barst RJ, Badesch DB, Frost AE, McGoon MD. An evaluation of long-term survival from time of diagnosis in pulmonary arterial hypertension from the REVEAL Registry. Chest. 2012 Aug;142(2):448-456. Available from: https://doi.org/10.1378/chest.11-1460
Morrell NW, Aldred MA, Chung WK, Elliott CG, Nichols WC, Soubrier F, et al. Genetics and genomics of pulmonary arterial hypertension. Eur Respir J. 2019 Jan;53(1):1801899. Available from: https://doi.org/10.1183/13993003.01899-2018
Soubrier F, Chung WK, Machado R, Grünig E, Aldred MA, Geraci M, et al. Genetics and genomics of pulmonary arterial hypertension. J Am Coll Cardiol. 2013 Dec 24;62(25 Suppl):D13–D21. Available from: https://doi.org/10.1016/j.jacc.2013.10.035
Humbert M, McLaughlin V, Gibbs JS, Gomberg-Maitland M, Hoeper MM, Preston IR, et al. Sotatercept for the treatment of pulmonary arterial hypertension. N Engl J Med. 2021 Apr 1;384(13):1204–1215. Available from: https://doi.org/10.1056/nejmoa2024277
Hoeper MM, Badesch DB, Ghofrani HA, Gibbs JSR, Gomberg-Maitland M, McLaughlin VV, et al. Phase 3 trial of sotatercept for treatment of pulmonary arterial hypertension. N Engl J Med. 2023 Apr 20;388(16):1478-1490. Available from: https://doi.org/10.1056/nejmoa2213558
Waxman AB, Systrom DM, Manimaran S, de Oliveira Pena J, Lu J, Rischard FP. SPECTRA phase 2b study: impact of sotatercept on exercise tolerance and right ventricular function in pulmonary arterial hypertension. Circ Heart Fail. 2024 May;17(5):e011227. Available from: https://doi.org/10.1161/circheartfailure.123.011227
U.S. Food and Drug Administration. FDA approves Winrevair (sotatercept-csrk) for adults with pulmonary arterial hypertension. FDA News Release. March 26, 2025. Available from: https://www.fda.gov/news-events/press-announcements/fda-approves-winrevair-sotatercept-csrk-adults-pulmonary-arterial-hypertension
Yung LM, Yang P, Joshi S, Augur ZM, Kim SSJ, Bocobo GA, et al. ACTRIIA-Fc rebalances activin/GDF versus BMP signaling in pulmonary hypertension. Sci Transl Med. 2020;12(543):eaaz5660. Available from: https://doi.org/10.1126/scitranslmed.aaz5660
Morrell NW, Bloch DB, ten Dijke P, Goumans MJ, Hata A, et al. Targeting BMP signalling in cardiovascular disease and anaemia. Nat Rev Cardiol. 2016;13(2):106-120. Available from: https://doi.org/10.1038/nrcardio.2015.156
Goumans MJ, Ten Dijke P. TGF-β signaling in control of cardiovascular function. Cold Spring Harb Perspect Biol. 2018;10(2):a022210. Available from: https://doi.org/10.1101/cshperspect.a022210
Ruckle J, Jacobs M, Kramer W, Pearsall AE, Kumar R, Underwood KW, et al. Single-dose, randomized, double-blind, placebo-controlled study of ACE-011 (ActRIIA-IgG1) in postmenopausal women. J Bone Miner Res. 2009;24(4):744-752. Available from: https://doi.org/10.1359/jbmr.081208
Raftopoulos H, Laadem A, Hesketh PJ, et al. Sotatercept (ACE-011) for the treatment of chemotherapy-induced anemia in patients with metastatic breast cancer or advanced or metastatic solid tumors treated with platinum-based chemotherapeutic regimens: results from two phase 2 studies. Support Care Cancer. 2016;24(4):1517-1525. Available from: https://doi.org/10.1007/s00520-015-2962-2
Goumans MJ, Liu Z, ten Dijke P. TGF-β signaling in vascular biology and dysfunction. Cell Res. 2009;19(1):116-127. Available from: https://doi.org/10.1038/cr.2008.326
Rol N, Kurakula KB, Happé C, Bogaard HJ, Goumans MJ, et al. TGF-β and BMPR2 signaling in PAH: two black sheep in one family. Int J Mol Sci. 2018;19(9):2585. Available from: https://doi.org/10.3390/ijms19092585
Galiè N, Manes A, Branzi A. The endothelin system in pulmonary arterial hypertension. Cardiovasc Res. 2004;61(2):227-237. Available from: https://doi.org/10.1016/j.cardiores.2003.11.026
Klinger JR, Elliott CG, Levine DJ, Bossone E, Duvall L, Fagan K, et al. Therapy for pulmonary arterial hypertension in adults: update of the CHEST guideline and expert panel report. Chest. 2019;155(3):565-586. Available from: https://doi.org/10.1016/j.chest.2018.11.030
Galiè N, Channick RN, Frantz RP, Grünig E, Jing ZC, Moiseeva O, et al. Risk stratification and medical therapy of pulmonary arterial hypertension. Eur Respir J. 2019;53(1):1801889. Available from: https://doi.org/10.1183/13993003.01889-2018
Channick RN, Frantz RP, Kawut SM. Sotatercept in patients with pulmonary arterial hypertension at high risk of clinical worsening: results from the ZENITH trial. N Engl J Med. 2025;392(13):1201-1212.
Merck & Co., Inc. Merck announces early termination of HYPERION trial of sotatercept in pulmonary arterial hypertension due to overwhelming efficacy. Press Release. January 15, 2025. Available from: https://www.merck.com/news/merck-announces-decision-to-stop-phase-3-hyperion-trial-evaluating-winrevair-sotatercept-csrk-early-and-move-to-final-analysis/
ClinicalTrials.gov. A study of sotatercept for the treatment of pulmonary hypertension associated with heart failure with preserved ejection fraction (CADENCE). NCT04945460. Available from: https://clinicaltrials.gov/study/NCT04945460. Accessed April 10, 2025.
Benza RL, Farber HW, Frost A. SOTERIA: one-year interim analysis of an open-label extension study of sotatercept for pulmonary arterial hypertension. Am J Respir Crit Care Med. 2024;209:A3809.
ClinicalTrials.gov. A study to evaluate the safety, tolerability, and efficacy of sotatercept in pediatric participants with pulmonary arterial hypertension (MOONBEAM). NCT05587712. Available from: https://clinicaltrials.gov/study/NCT05587712. Accessed April 10, 2025.
U.S. Food and Drug Administration. Winrevair (sotatercept-csrk) prescribing information. March 2025.
Galiè N, Olschewski H, Oudiz RJ, Torres F, Frost A, Ghofrani HA, et al. Ambrisentan for the treatment of pulmonary arterial hypertension: results of the ambrisentan in pulmonary arterial hypertension, randomized, double-blind, placebo-controlled, multicenter, efficacy (ARIES) study 1 and 2. Circulation. 2008;117(23):3010-3019. Available from: https://doi.org/10.1161/circulationaha.107.742510
Galiè N, Ghofrani HA, Torbicki A, Barst RJ, Rubin LJ, Badesch D, et al. Sildenafil citrate therapy for pulmonary arterial hypertension. N Engl J Med. 2005;353(20):2148-2157. Available from: https://doi.org/10.1056/nejmoa050010
Barst RJ, Rubin LJ, Long WA, McGoon MD, Rich S, Badesch DB, et al. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. N Engl J Med. 1996;334(5):296-301. Available from: https://doi.org/10.1056/nejm199602013340504
Galiè N, Barberà JA, Frost AE, Ghofrani HA, Hoeper MM, McLaughlin VV, et al. Initial use of ambrisentan plus tadalafil in pulmonary arterial hypertension. N Engl J Med. 2015;373(9):834-844. Available from: https://doi.org/10.1056/nejmoa1413687
Petrović M, Locatelli I, Bernjak A. A comparative study of the efficacy of endothelin receptor antagonists and phosphodiesterase type 5 inhibitors for pulmonary arterial hypertension: a meta-analysis of randomized controlled trials. Respir Med. 2020;171:106101. Available from: https://doi.org/10.1016/j.rmed.2020.106101
Sitbon O, Channick R, Chin KM, Frey A, Gaine S, Galiè N, et al. Selexipag for the treatment of pulmonary arterial hypertension. N Engl J Med. 2015;373(26):2522-2533. Available from: https://doi.org/10.1056/nejmoa1503184
Pulido T, Adzerikho I, Channick RN, Delcroix M, Galiè N, Ghofrani HA, et al. Macitentan and morbidity and mortality in pulmonary arterial hypertension. N Engl J Med. 2013;369(9):809-818. Available from: https://doi.org/10.1056/nejmoa1213917
Vachiéry JL, Tedford RJ, Rosenkranz S, Palazzini M, Lang I, Guazzi M, et al. Pulmonary hypertension due to left heart disease. Eur Respir J. 2019;53(1):1801897. Available from: https://doi.org/10.1183/13993003.01897-2018
Rosenzweig EB, Abman SH, Adatia I, Beghetti M, Bonnet D, Haworth S, et al. Paediatric pulmonary arterial hypertension: updates on definition, classification, diagnostics and management. Eur Respir J. 2019;53(1):1801916. Available from: https://doi.org/10.1183/13993003.01916-2018
Chung L, Farber HW, Benza R, Miller DP, Parsons L, Hassoun PM, et al. Unique predictors of mortality in patients with pulmonary arterial hypertension associated with systemic sclerosis in the REVEAL registry. Chest. 2014;146(6):1494-1504. Available from: https://doi.org/10.1378/chest.13-3014
Sitbon O, Gressin V, Speich R, Macdonald PS, Opravil M, Cooper DA, et al. Bosentan for the treatment of human immunodeficiency virus-associated pulmonary arterial hypertension. Am J Respir Crit Care Med. 2004;170(11):1212-1217. Available from: https://doi.org/10.1164/rccm.200404-445oc
Nathan SD, Barbera JA, Gaine SP, Harari S, Martinez FJ, Olschewski H, et al. Pulmonary hypertension in chronic lung disease and hypoxia. Eur Respir J. 2019;53(1):1801914. Available from: https://doi.org/10.1183/13993003.01914-2018
Sikirica M, Iorga SR, Bancroft T, Potash J. The economic burden of pulmonary arterial hypertension (PAH) in the US on payers and patients. BMC Health Serv Res. 2014;14:676. Available from: https://doi.org/10.1186/s12913-014-0676-0